Vytrus Biotech, member of CataloniaBio & HealthTech, has received €575,000 in financing from the Center for Technological Development and Innovation (CDTI), affiliated with the Ministry of Science and Innovation of the Spanish Government, for the development of cutting-edge technologies in the field of dermocosmetics and health.
Out of the total funded amount, €137,000 is non-refundable (grant), while the remaining amount is a long-term loan for the company. Vytrus will use this funding to develop new technological platforms to produce hybrid active ingredients with high potential for health and human well-being.
According to Albert Jané, CEO and co-founder of Vytrus Biotech: "This research project will be of great help for Vytrus Biotech to maintain a high level of innovation and at the same time diversify the company's portfolio of highly effective, sustainable, and innovative products."
The financing granted by CDTI for the project has received co-financing from the Next Generation Funds, channelled through the ERDF (European Regional Development Fund of the European Union). The company also acknowledges the support provided by the organization during the operation for its successful completion.
Vytrus Biotech annually allocates around 20% of its turnover to R&D activities. This continuous effort has positioned it as a benchmark for innovation and sustainability in the field of active dermocosmetic ingredients. The company currently markets 19 products and aims to launch 10 new ingredients in the next 4 years as part of its strategic plan.
Comments